Stocksigma LogoStocksigma Logo

Piramal Pharma Reports Strong Q2FY27 Results and Upgrades Full-Year Guidance

Piramal Pharma delivered strong Q2FY27 consolidated performance, with revenue from operations growing 28% YoY to ₹2,617 Cr and EBITDA surging 72% YoY to

Piramal Pharma Reports Strong Q2FY27 Results and Upgrades Full-Year Guidance

Piramal Pharma Ltd · Press Release · 28 Oct 2026, 2:34 am

Piramal Pharma Reports Strong Q2FY27 Results and Upgrades Full-Year Guidance Piramal Pharma delivered strong Q2FY27 consolidated performance, with revenue from operations growing 28% YoY to ₹2,617 Cr and EBITDA surging 72% YoY to ₹385 Cr, expanding margins by 372 bps YoY to 14.7%. PAT turned positive at ₹5 Cr versus a ₹99 Cr loss in Q2FY26. Growth was led by CDMO (+36% YoY to ₹1,424 Cr) and CHG (+32% YoY to ₹849 Cr). Driven by robust H1 order inflows, the company upgraded its FY27 revenue growth guidance to 19%-20% with meaningfully higher profitability.

Original exchange filing (PDF)

More announcements from Piramal Pharma Ltd

All Piramal Pharma Ltd announcements